AIM ImmunoTech Resumes Trading on NYSE American

Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [2] - The company's lead product is Ampligen (rintatolimod), a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator, showing broad spectrum activity in clinical trials [2] Trading Information - AIM ImmunoTech Inc.'s common stock has resumed trading on the NYSE American under the ticker symbol "AIM" effective June 17, 2025 [1]